About Editas Medicine
Editas Medicine is a company based in Cambridge (United States) founded in 2013 by George M Church.. Editas Medicine has raised $210 million across 5 funding rounds from investors including Fidelity Investments, Juno Therapeutics and Dr. Reddy's Laboratories. The company has 246 employees as of December 31, 2024. Editas Medicine offers products and services including CRISPR Gene Editing Technology and Experimental Medicines Pipeline. Editas Medicine operates in a competitive market with competitors including Insitro, BridgeBio, Alnylam, ATAI and Forge Biologics, among others.
- Headquarter Cambridge, United States
- Employees 246 as on 31 Dec, 2024
- Founders George M Church
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Editas Medicine, Inc.
-
Annual Revenue
$32.31 M-58.64as on Dec 31, 2024
-
Net Profit
$-237.09 M-54.74as on Dec 31, 2024
-
EBITDA
$-233.11 M-42.91as on Dec 31, 2024
-
Total Equity Funding
$210 M (USD)
in 5 rounds
-
Latest Funding Round
$2 M (USD), Post-IPO
Dec 29, 2023
-
Investors
Fidelity Investments
& 17 more
-
Employee Count
246
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Editas Medicine
Editas Medicine is a publicly listed company on the NASDAQ with ticker symbol EDIT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Editas Medicine
Editas Medicine offers a comprehensive portfolio of products and services, including CRISPR Gene Editing Technology and Experimental Medicines Pipeline. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Technology for revising, removing, and replacing DNA to treat serious diseases.
Pipeline of medicines aimed at developing durable therapies for patients.
Unlock access to complete
Unlock access to complete
Funding Insights of Editas Medicine
Editas Medicine has successfully raised a total of $210M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $2 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $2.0M
-
First Round
First Round
(25 Nov 2013)
- Investors Count 18
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2023 | Amount | Post-IPO - Editas Medicine | Valuation |
investors |
|
| Aug, 2015 | Amount | Series B - Editas Medicine | Valuation | Boris Nikoli | |
| Jul, 2015 | Amount | Grant - Editas Medicine | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Editas Medicine
Editas Medicine has secured backing from 18 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Fidelity Investments, Juno Therapeutics and Dr. Reddy's Laboratories. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Founded Year | Domain | Location | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Founded Year | Domain | Location | |
|
Corporate backed venture capital fund investing in multiple sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Editas Medicine
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Editas Medicine
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Editas Medicine Comparisons
Competitors of Editas Medicine
Editas Medicine operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, Alnylam, ATAI and Forge Biologics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Editas Medicine
Frequently Asked Questions about Editas Medicine
When was Editas Medicine founded?
Editas Medicine was founded in 2013.
Where is Editas Medicine located?
Editas Medicine is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Editas Medicine?
Cynthia Collins is the current CEO of Editas Medicine.
Is Editas Medicine a funded company?
Editas Medicine is a funded company, having raised a total of $210M across 5 funding rounds to date. The company's 1st funding round was a Grant of $220.43K, raised on Nov 25, 2013.
How many employees does Editas Medicine have?
As of Dec 31, 2024, the latest employee count at Editas Medicine is 246.
What is the annual revenue of Editas Medicine?
Annual revenue of Editas Medicine is $32.31M as on Dec 31, 2024.
What does Editas Medicine do?
Developer of therapeutics for rare genetic diseases. It has developed a novel class of genome editing therapeutics using CRISPRCas genome editing technology. It is utilized for the treatment of rare genetic eye diseases including Leber congenital amaurosis, and usher syndrome. It is also used for the treatment of beta-thalassemia, Duchenne muscular dystrophy, sickle cell anemia, cystic fibrosis, alpha 1-antitrypsin deficiency, and many more.
Who are the top competitors of Editas Medicine?
Editas Medicine's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does Editas Medicine offer?
Editas Medicine offers CRISPR Gene Editing Technology and Experimental Medicines Pipeline.
Is Editas Medicine publicly traded?
Yes, Editas Medicine is publicly traded on NASDAQ under the ticker symbol EDIT.
Who are Editas Medicine's investors?
Editas Medicine has 18 investors. Key investors include Fidelity Investments, Juno Therapeutics, Dr. Reddy's Laboratories, Khosla Ventures, and T. Rowe Price.
What is Editas Medicine's ticker symbol?
The ticker symbol of Editas Medicine is EDIT on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.